Prabagar Miglena G, Choi Hyeong-jwa, Park Jin-Yeon, Loh Sohee, Kang Young-Sun
Department of Biomedical Science and Technology, SMART Institute of Advanced Biomedical Science, Institute of Functional Genomics, Konkuk University, 1 Hwayang-dong, Gwangjin-gu, Seoul, 143-701, Republic of Korea.
Clin Exp Med. 2014 Nov;14(4):361-73. doi: 10.1007/s10238-013-0255-4. Epub 2013 Sep 1.
Immunoglobulins are glycoproteins produced by the cells of the immune system. Their primary function is to protect the body from pathogenic infection. Moreover, a concentrated polyclonal mixture of immunoglobulin G (IgG), the so-called intravenous IgG (IVIG), has been used to treat various chronic and systemic disorders of the immune system. Studies on the effects of IVIG in autoimmune disease models have revealed that IgG Fc fragments confer protection against various autoimmune diseases. The identification of this IgG Fc immunomodulatory component is important for the development of IVIG substitutes. The focus of this review is to introduce one of the Fc regulatory entities and to provide a summary of the current knowledge of the putative general mechanisms underlying IVIG activity in vivo on the basis of these Fc fragments. We also address the recent insights into several approaches for the development of IVIG substitutes.
免疫球蛋白是由免疫系统细胞产生的糖蛋白。它们的主要功能是保护身体免受病原体感染。此外，免疫球蛋白G（IgG）的浓缩多克隆混合物，即所谓的静脉注射免疫球蛋白（IVIG），已被用于治疗免疫系统的各种慢性和全身性疾病。对IVIG在自身免疫性疾病模型中的作用研究表明，IgG Fc片段可抵御各种自身免疫性疾病。鉴定这种IgG Fc免疫调节成分对于开发IVIG替代品很重要。本综述的重点是介绍一种Fc调节实体，并基于这些Fc片段总结目前对IVIG体内活性潜在一般机制的认识。我们还讨论了开发IVIG替代品的几种方法的最新见解。
